Pharming (PHAR) Equity Income (2021 - 2023)
Pharming's (PHAR) quarterly Equity Income came in at -$12.2 million in Q1 2023, down 448.57% YoY from $3.5 million in Q1 2022, and down 448.57% on a QoQ basis from $3.5 million in Q1 2022.
Pharming (PHAR) Equity Income (2021 - 2023) Analysis & Trends
Pharming (PHAR) has 3 years of Equity Income data on file, last reported at -$12.2 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -12.20 Mn |
| Mar 31, 2022 | 3.50 Mn |
| Mar 31, 2021 | 8.50 Mn |